Equity Field Notes from temporal sources

[DanWebzster]

AXON (update)

AXON transformed itself into a gene therapy company by acquiring a second generation Parkinson treatment

All approved PD therapies treat symptoms. This therapy is intended to reverse/control progression

OXB-102 delivers 3 genes that encode for enzymes required to synthesize dopamine.

AXON will conduct a Ph1 dose escalation study followed by a Ph2 double blind sham study.

The investigation for the first generation of this treatment failed to demonstrate efficacy and did not test for increased dopamine levels. If the AXON's investigations do not test for increased dopamine levels, the results will be very controversial

6/22/18 filed for $75mn ATM financing